A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Northwestern University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
TerSera Therapeutics LLC
Alliance for Clinical Trials in Oncology
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
University Health Network, Toronto
M.D. Anderson Cancer Center
Mayo Clinic
Novartis
M.D. Anderson Cancer Center
University of California, San Diego
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
GlaxoSmithKline
GlaxoSmithKline
Novartis
SCRI Development Innovations, LLC
Roswell Park Cancer Institute
Georgetown University
Brown University
GlaxoSmithKline
GlaxoSmithKline
OHSU Knight Cancer Institute
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
GlaxoSmithKline
Teva Branded Pharmaceutical Products R&D, Inc.